ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced a proposed placing, raising a minimum of £3 million (before expenses), via the issue of new ordinary
Immupharma Chairman presents to investors at the Biotech Capital Conference. Video source: Stocktube ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock
A market study, titled “Global Autoimmune Drugs Market 2016-2020,” has been featured on MarketResearchReports.biz’s online repository of market intelligence. This research report provides the answers to some of the pertinent
Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) spoke to Proactive Investors & gave an update on the company’s progress with its phase-III clinical trial of Lupuzor, a treatment for Lupus
ImmuPharma’s Tim McCarthy discusses their Phase III Lupuzor trial; why the completion of patient recruitment on track is important, the significance of the 70 patients dosed in the US, safety profile and its importance, the market potential for Lupuzor if approved and their key milestones for 2017/2018 in this exclusive interview with DirectorsTalk
Northland Capital Partners’ Vadim Alexandre discusses the latest update from ImmuPharma PLC on their Lupuzor Phase III study in this exclusive interview with DirectorsTalk
Immupharma Plc (LON:IMM) Non-Executive Chairman Tim McCarthy talks to DirectorsTalk about its phase 3 trial of Lupuzor. Tim explains the importance of completing the recruitment of the 200 patients and
Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk about the phase III trial update announced by Immupharma Plc (LON:IMM). Vadim talks us through the highlights and the
Northland Capital partners view on Immupharma PLC LON:IMM: Today’s announcement provides further details on ImmuPharma’s flagship Phase 3 clinical trial. With enrolment and dosing now complete, we have better visibility
Immupharma Plc (LON:IMM) are the topic of conversation when Vadim Alexandre, head of research at Northland Capital Partners talks to DirectorsTalk about being its nominated adviser / sole broker. Vadim
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
